8-K: Kineta Reopens Enrollment for VISTA-101 Cancer Clinical Trial After Funding Issues Resolved

Kineta has resumed enrollment in its VISTA-101 Phase 1/2 clinical trial for KVA12123, a VISTA blocking immunotherapy, after a temporary suspension due to funding issues.

Summary

• Kineta has announced the reopening of enrollment for its VISTA-101 Phase 1/2 clinical trial, which is evaluating KVA12123 in patients with advanced solid tumors.
• The trial had been suspended in March 2024 due to investors not fulfilling their funding obligations.
• The trial includes both a monotherapy arm with KVA12123 and a combination arm using KVA12123 with Merck's KEYTRUDA (pembrolizumab).
• Thirty patients have been enrolled to date, and Kineta anticipates full enrollment by the end of 2024.
• Initial results from the trial showed partial response and stable disease in the combination cohorts and durable stable disease in the monotherapy cohorts.
• KVA12123 has demonstrated a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome.
• Kineta has entered into an agreement with TuHURA Biosciences, which includes a $5 million nonrefundable payment and an exclusive right for TuHURA to acquire Kineta's KVA12123 assets.

Sentiment

Score: 7

Explanation: The document is generally positive due to the resumption of the clinical trial and the partnership with TuHURA, but there are still risks and uncertainties related to funding and the potential acquisition of assets.

Positives

• The resumption of enrollment in the VISTA-101 trial is a positive step for the development of KVA12123.
• Initial clinical results show promising signs of efficacy with partial responses and stable disease observed.
• KVA12123 has demonstrated a favorable safety and tolerability profile.
• The $5 million nonrefundable payment from TuHURA provides immediate financial benefit to Kineta.
• The agreement with TuHURA could lead to a potential acquisition of KVA12123 assets, providing further value to Kineta.

Negatives

• The trial was previously suspended due to funding issues, highlighting financial vulnerabilities.
• The exclusive right granted to TuHURA could limit Kineta's options for KVA12123 if TuHURA does not proceed with an acquisition.
• The company had a significant corporate restructuring in February 2024 to reduce expenses and preserve cash.

Risks

• There is a risk that the clinical trial may not be completed successfully or that the results may not be as positive as initially indicated.
• The agreement with TuHURA may not result in a definitive acquisition of KVA12123 assets.
• Kineta faces risks related to the volatility and uncertainty in the capital markets for biotechnology companies.
• The company's cash resources may not be sufficient to fund its operating expenses and capital requirements.
• There is a risk of litigation against investors who failed to close an anticipated private placement.

Future Outlook

Kineta is focused on completing enrollment in the VISTA-101 trial by the end of 2024 and is exploring strategic alternatives to maximize stockholder value. The company is also working with TuHURA on the potential acquisition of KVA12123 assets.

Management Comments

• Thierry Guillaudeux, Chief Scientific Officer of Kineta, stated that they are pleased to resume enrollment for VISTA-101 and are encouraged by the initial data.
• James A. Bianco, Chief Executive Officer of TuHURA, said that the completion of the enrollment in the Phase 1 portion of the trial this year is an important milestone.

Industry Context

This announcement is relevant to the immuno-oncology sector, where companies are developing novel therapies to address cancer immune resistance. The resumption of the trial and the agreement with TuHURA highlight the ongoing interest in VISTA-blocking immunotherapies.

Comparison to Industry Standards

• The VISTA-101 trial is a Phase 1/2 study, which is a common stage for early clinical development of novel cancer therapies.
• The use of pembrolizumab (KEYTRUDA) in the combination arm is a standard approach in immuno-oncology trials, as it is a well-established checkpoint inhibitor.
• The reported partial responses and stable disease are typical endpoints for early-stage oncology trials, and the absence of dose-limiting toxicities is a positive sign.
• Other companies developing similar immunotherapies include those targeting PD-1/PD-L1, CTLA-4, and other immune checkpoints. Kineta's VISTA-blocking approach is a differentiated strategy.
• The agreement with TuHURA is similar to other strategic partnerships and licensing deals in the biotech industry, where smaller companies collaborate with larger ones to advance their drug candidates.

Stakeholder Impact

• Shareholders may view the resumption of the trial and the agreement with TuHURA positively.
• Employees may be impacted by the corporate restructuring and the potential acquisition of assets.
• Patients with advanced solid tumors may benefit from the development of KVA12123.
• Potential partners and investors may be interested in the progress of the clinical trial and the strategic alternatives being explored.

Next Steps

• Kineta will continue to enroll patients in the VISTA-101 trial.
• Kineta will work with TuHURA on the potential acquisition of KVA12123 assets.
• Kineta will continue to explore strategic alternatives to maximize stockholder value.

Key Dates

Keywords

Kineta, KVA12123, VISTA-101, Clinical Trial, Immunotherapy, Oncology, TuHURA Biosciences, Cancer, Pembrolizumab, KEYTRUDA